In medical terms, AUB stands for Abnormal Uterine Bleeding. It refers to any variation from a normal menstrual cycle in terms of frequency, regularity, duration, or volume of blood flow in non-pregnant individuals of reproductive age, as well as any uterine bleeding that occurs after menopause.
The Evolution of Menstrual Terminology: Why AUB Replaced Legacy Terms
For decades, clinical gynecology relied on an array of Latin and Greek terms to describe menstrual disorders. Terms such as menorrhagia (excessively heavy menstrual flow), metrorrhagia (bleeding between regular periods), polymenorrhea (frequent cycles), and dysfunctional uterine bleeding (DUB) were widely used by clinicians. However, these terms lacked standardized definitions, creating confusion among healthcare providers, clinical researchers, and patients.
To establish global consistency in clinical practice and scientific literature, the International Federation of Gynecology and Obstetrics (FIGO) introduced a standardized nomenclature system. The universal term Abnormal Uterine Bleeding (AUB) was established to encompass all variations of irregular or excessive uterine bleeding, while the umbrella term dysfunctional uterine bleeding was formally retired.
Under current clinical standards published by FIGO and supported by the American College of Obstetricians and Gynecologists (ACOG), AUB is described using clear, objective parameters rather than subjective legacy terms. A normal menstrual cycle typically occurs every 24 to 38 days, lasts 8 days or fewer, and involves predictable blood loss that does not interfere with physical or social wellbeing. Any deviation outside these boundaries—whether in frequency, duration, volume, or intermenstrual timing—is categorized clinically as AUB.
The FIGO PALM-COEIN Classification System
To help clinicians diagnose and treat the underlying causes of abnormal uterine bleeding, FIGO developed the PALM-COEIN (pronounced palm-coin) classification system. This system divides potential etiologies into structural components that can be visually or histologically evaluated (PALM) and non-structural components that cannot be identified through structural imaging alone (COEIN).
- Abnormal Uterine Bleeding (AUB)
- PALM Structural
- Polyp (AUB-P)
- Adenomyosis (AUB-A)
- Leiomyoma (AUB-L)
- Malignancy & Hyperplasia (AUB-M)
- COEIN Non-Structural
- Coagulopathy (AUB-C)
- Ovulatory Dysfunction (AUB-O)
- Endometrial Disorders (AUB-E)
- Iatrogenic (AUB-I)
- Not Otherwise Classified (AUB-N)
- PALM Structural
Structural Causes (PALM)
1. Polyps (AUB-P)
Endometrial and cervical polyps are hyperplastic overgrowths of glandular tissue and stroma attached to the uterine wall or cervix. While predominantly benign, polyps can cause localized vascular fragility, leading to intermenstrual spotting, postcoital bleeding, or heavy menstrual flow. They are identified via transvaginal ultrasonography or direct visualization during hysteroscopy.
2. Adenomyosis (AUB-A)
Adenomyosis occurs when endometrial tissue invades the muscular wall of the uterus (the myometrium). This causes localized or diffuse enlargement of the uterus, disruption of normal myometrial contractions, and persistent low-grade inflammation. Patients frequently present with painful periods (dysmenorrhea) alongside heavy, prolonged menstrual bleeding.
3. Leiomyoma / Fibroids (AUB-L)
Leiomyomas, commonly known as uterine fibroids, are non-cancerous smooth muscle tumors of the uterus. The impact of a fibroid on bleeding depends heavily on its anatomical location. FIGO subclassifies fibroids into:
- Submucosal fibroids (AUB-LSM): Distort the uterine cavity directly, causing severe, rapid hemorrhage and prolonged bleeding due to endometrial ulceration and impaired vascular contractility.
- Other fibroids (AUB-LO): Intramural or subserosal fibroids that alter uterine mechanics or increase overall organ vascularity without directly contacting the inner cavity.
4. Malignancy and Hyperplasia (AUB-M)
This category encompasses premalignant hyperplasias (such as endometrial intraepithelial neoplasia) and overt malignancies of the female reproductive tract, including endometrial carcinoma or uterine sarcoma. AUB-M is a critical diagnostic consideration in postmenopausal individuals presenting with any vaginal bleeding, as well as in younger individuals with high-risk features such as prolonged anovulation, obesity, or Lynch syndrome.
Non-Structural Causes (COEIN)
1. Coagulopathy (AUB-C)
Systemic disorders of blood coagulation can manifest primarily as heavy menstrual bleeding. The most common hereditary etiology is von Willebrand disease (vWD), though platelet function disorders, factor deficiencies, and severe liver disease also fall under AUB-C. Screening for AUB-C is indicated when heavy menstrual bleeding dates back to menarche or is accompanied by systemic bleeding signs, such as frequent epistaxis (nosebleeds), easy bruising, or heavy bleeding following dental procedures.
2. Ovulatory Dysfunction (AUB-O)
When normal ovulation fails to occur (anovulation), the ovary does not produce a corpus luteum, leading to a lack of progesterone secretion. Unopposed estrogen continues to cause the endometrial lining to proliferate without periodic structural breakdown. Eventually, the fragile, thickened endometrium outgrows its blood supply, resulting in unpredictable, heavy, and prolonged breakthrough bleeding. Common causes include:
- Polycystic Ovary Syndrome (PCOS)
- Thyroid disorders (hypothyroidism or hyperthyroidism)
- Hyperprolactinemia
- Extreme stress, rapid weight changes, or intense physical exercise
3. Endometrial Primary Disorders (AUB-E)
AUB-E is diagnosed when abnormal bleeding occurs in individuals with regular ovulatory cycles and no detectable structural abnormalities or systemic coagulopathies. The underlying pathophysiology involves primary cellular defects within the endometrium, such as impaired vasoconstriction (due to deficient prostaglandin production), deficient tissue repair mechanisms, or localized microvascular breakdown.
4. Iatrogenic Causes (AUB-I)
Iatrogenic bleeding stems directly from medical treatments, medications, or inserted devices. Common causes include:
- Intrauterine devices (copper or levonorgestrel-releasing systems), particularly during the initial months following insertion
- Exogenous hormonal therapies (breakthrough bleeding from oral contraceptives, progestin-only implants, or hormone replacement therapy)
- Systemic anticoagulants (warfarin, direct oral anticoagulants) and antiplatelet agents
- Psychotropic medications that elevate systemic prolactin levels
5. Not Otherwise Classified (AUB-N)
This category serves as a diagnostic repository for rare, poorly understood, or ill-defined conditions that cause abnormal bleeding, such as uterine arteriovenous malformations (AVMs), chronic endometritis, or myometrial hypertrophy without adenomyosis.
Detailed Comparison of Structural vs. Non-Structural AUB Etiologies
The following table summarizes the structural (PALM) and non-structural (COEIN) classification categories to assist in clinical differentiation and evaluation:
| Category Code | Etiology | Structural vs. Non-Structural | Typical Clinical Presentation | Primary Diagnostic Tools | Primary Clinical Strategy |
|---|---|---|---|---|---|
| AUB-P | Polyps | Structural | Intermenstrual spotting, light irregular bleeding | Transvaginal Ultrasound (TVUS), Hysteroscopy | Hysteroscopic resection, biopsy |
| AUB-A | Adenomyosis | Structural | Dysmenorrhea, heavy flow, enlarged tender uterus | Pelvic MRI, High-resolution TVUS | LNG-IUD, NSAIDs, ablation, hysterectomy |
| AUB-L | Leiomyoma (Fibroids) | Structural | Heavy prolonged flow, pelvic pressure, anemia | TVUS, Saline Infusion Sonography (SIS) | Myomectomy, UAE, GnRH modulators |
| AUB-M | Malignancy & Hyperplasia | Structural | Postmenopausal bleeding, severe irregular bleeding | Endometrial biopsy, Hysteroscopy | Surgical staging, hysterectomy, oncology referral |
| AUB-C | Coagulopathy | Non-Structural | Heavy bleeding since menarche, easy bruising | Coagulation panel, von Willebrand panel | Hemostatic therapy (TXA), desmopressin, hematology consult |
| AUB-O | Ovulatory Dysfunction | Non-Structural | Irregular, unpredictable timing, missed periods then heavy flow | TSH, Prolactin, Androgen panel, pelvic ultrasound | Hormonal regulation (COCs, progestins), lifestyle interventions |
| AUB-E | Endometrial | Non-Structural | Cyclical heavy flow with normal regular cycle timing | Diagnosis of exclusion, endometrial sampling | Antifibrinolytics (TXA), NSAIDs, hormonal management |
| AUB-I | Iatrogenic | Non-Structural | Unscheduled breakthrough spotting during drug therapy | Detailed medication review, compliance check | Adjustment of dosage, changing delivery method, medication switch |
| AUB-N | Not Otherwise Classified | Non-Structural / Rare | Variable, persistent heavy bleeding unresponsive to standard care | Color Doppler TVUS, Angiography, Endometrial culture | Targeted procedural care (e.g., AVM embolization), antibiotics |
Diagnostic Evaluation of Abnormal Uterine Bleeding
Evaluating a patient for AUB involves a structured diagnostic approach to pinpoint the exact category within the PALM-COEIN framework.
- Patient Presenting with AUB
- Medical History & Physical, Speculum & Bimanual Exam
- Laboratory Workup (hCG, CBC, TSH, Coagulation)
- Pelvic Ultrasound (TVUS)
- Structural Lesion Identified
- Saline Infusion Sonography (SIS)
- Hysteroscopy / Biopsy
- No Structural Lesion (COEIN)
- Targeted Lab Panels (Endocrine/Coag)
- Endometrial Biopsy (If risk factors or age >45)
- Structural Lesion Identified
Initial Clinical Assessment
The diagnostic process begins with a detailed clinical history to characterize the pattern, volume, frequency, and duration of bleeding. Clinicians evaluate systemic symptoms, medication use, underlying medical conditions, and family history of bleeding disorders or gynecologic cancers. A physical examination includes a pelvic exam with speculum visualization to rule out non-uterine bleeding sources, such as cervical erosion, vaginal lacerations, or rectal disorders.
Laboratory Testing
- Pregnancy Test: A serum or urine beta-human chorionic gonadotropin ($\beta$-hCG) test is mandatory in reproductive-age individuals to exclude pregnancy complications (such as ectopic pregnancy, threatened abortion, or gestational trophoblastic disease).
- Complete Blood Count (CBC): Assesses hemoglobin and hematocrit levels to detect anemia resulting from chronic or acute blood loss.
- Targeted Endocrine Panels: Thyroid-stimulating hormone (TSH) and serum prolactin levels evaluate potential ovulatory dysfunction (AUB-O).
- Coagulation Screening: Indicated in cases of severe unexplained heavy menstrual bleeding, particularly when present since menarche.
- Serum Ferritin: Evaluates total body iron stores to detect iron deficiency prior to the onset of overt anemia.
Diagnostic Imaging
- Transvaginal Ultrasonography (TVUS): The first-line imaging modality for evaluating uterine structure. TVUS allows for detailed measurement of endometrial thickness and visual identification of fibroids, adenomyosis, and endometrial polyps.
- Saline Infusion Sonohysterography (SIS): Involves instilling sterile saline into the uterine cavity during ultrasound imaging. This enhances visualization of intracavitary lesions like submucosal fibroids and small polyps.
- Pelvic Magnetic Resonance Imaging (MRI): Reserved for complex cases, such as mapping fibroids prior to myomectomy or accurately mapping deep adenomyosis.
Tissue Sampling and Hysteroscopy
- Endometrial Biopsy: Performed in-office using a flexible suction cannula (such as a Pipelle). Guidelines from the National Institutes of Health (NIH) and ACOG recommend tissue sampling for all individuals over age 45 presenting with AUB, as well as younger patients with risk factors for endometrial neoplasia (such as persistent anovulation, obesity, or family history of Lynch syndrome).
- Diagnostic Hysteroscopy: Direct visualization of the uterine cavity using an endoscope passed through the cervix. This enables targeted biopsy or immediate removal of focal lesions like polyps.
Clinical Management and Treatment Strategies
Treatment for AUB is tailored to the specific PALM-COEIN category, the severity of symptoms, whether the patient desires future fertility, and their general medical history.
- AUB Treatment Modalities
- Medical Management
- Non-Hormonal (NSAIDs, TXA)
- Hormonal (LNG-IUD, COCs, Progestins)
- Targeted Hemostatic (Desmopressin)
- Surgical Interventions
- Polypectomy / Myomectomy (Hysteroscopic)
- Endometrial Ablation (Non-fertility)
- Hysterectomy (Definitive)
- Medical Management
Medical Treatments
Non-Hormonal Therapies
- Tranexamic Acid (TXA): An antifibrinolytic agent that prevents the breakdown of blood clots in the endometrium. Taken only during active menstrual bleeding, TXA reduces blood loss volume without altering systemic hormonal balances.
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Medications such as mefenamic acid or ibuprofen inhibit cyclooxygenase enzymes, reducing excess endometrial prostaglandin synthesis. NSAIDs can decrease menstrual blood loss by 20% to 50% and relieve dysmenorrhea.
Hormonal Therapies
- Levonorgestrel-Releasing Intrauterine System (LNG-IUD): Releases progestin directly into the uterine cavity, inducing endometrial atrophy. It is one of the most effective medical treatments for heavy menstrual bleeding, often reducing menstrual blood loss by over 80% within a few months.
- Combined Oral Contraceptive Pills (COCs): Regulate cycle timing, thin the endometrial lining, and suppress ovulatory fluctuations in patients with AUB-O or AUB-E.
- Oral Progestin Therapy: Cyclical or continuous administration of medroxyprogesterone acetate or norethindrone suppresses endometrial growth, which is particularly helpful for managing anovulatory cycles.
- Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists: Temporarily induce a hypoestrogenic state to suppress menstrual bleeding and shrink leiomyomas prior to planned surgical procedures.
Surgical Interventions
- Hysteroscopic Polypectomy or Myomectomy: Surgical removal of intracavitary polyps or submucosal fibroids using hysteroscopic instruments, preserving overall uterine structure and fertility potential.
- Endometrial Ablation: Resection or thermal destruction of the endometrial lining. This minimally invasive option is suitable for individuals with heavy bleeding who have finished childbearing and wish to avoid major surgery.
- Uterine Artery Embolization (UAE): A minimally invasive interventional radiology procedure that blocks blood flow to uterine fibroids, causing them to shrink over time.
- Myomectomy: Surgical excision of fibroids via laparoscopic, robotic, or open abdominal approaches, preserving the uterus for future pregnancy.
- Hysterectomy: Complete surgical removal of the uterus. Hysterectomy is a definitive cure for AUB when medical and less invasive surgical options are ineffective, contraindicated, or declined by the patient.
When to Seek Urgent Medical Care
While many forms of abnormal uterine bleeding can be evaluated in an outpatient clinical setting, acute, severe hemorrhage requires immediate emergency care.
Red Flag Symptoms Requiring Emergency Assessment:
- Soaking through two or more heavy-absorbency pads or tampons per hour for two consecutive hours.
- Passing blood clots larger than the size of a quarter.
- Signs of hemodynamic instability, such as dizziness, lightheadedness, fainting (syncope), or confusion.
- Shortness of breath or rapid heart rate (tachycardia) during exertion or rest.
- Vaginal bleeding during confirmed or suspected pregnancy.
- Vaginal bleeding accompanied by fever, chills, or severe pelvic pain (which may indicate pelvic inflammatory disease or tubo-ovarian abscess).
Professional Advice Limitation
This article is provided strictly for educational and informational purposes and does not constitute formal medical advice, diagnosis, or treatment. Diagnostic pathways, prescription dosages, and surgical recommendations vary based on individual clinical presentations and underlying health conditions. Readers experiencing symptoms of abnormal uterine bleeding should consult a qualified healthcare provider or board-certified obstetrician-gynecologist for personalized diagnostic evaluation and medical care.
Frequently Asked Questions
What does AUB mean in a doctor's diagnosis note?
In a clinical chart, AUB stands for Abnormal Uterine Bleeding. It indicates that your provider has documented bleeding from the uterus that strays from regular menstrual parameters in volume, frequency, duration, or timing, or bleeding that occurs post-menopause.
Is AUB always a sign of uterine cancer?
No. The majority of AUB cases stem from benign structural conditions (such as polyps or fibroids) or non-structural disruptions (such as hormonal imbalances or medication side effects). However, because endometrial cancer can present as abnormal bleeding—especially in postmenopausal individuals—gynecologists treat AUB as a priority symptom requiring structured evaluation.
What is the difference between AUB and DUB?
AUB (Abnormal Uterine Bleeding) is the modern, standardized overarching term for any abnormal bleeding from the uterus. DUB (Dysfunctional Uterine Bleeding) is an outdated legacy term that was previously used to describe abnormal bleeding without a clear structural cause. FIGO formally retired the term DUB in favor of specific categories like AUB-O (Ovulatory) or AUB-E (Endometrial).
Can stress cause AUB?
Yes. Severe physical or psychological stress can disrupt the hypothalamic-pituitary-ovarian axis, interfering with the signaling hormones needed for regular ovulation. This leads to anovulatory cycles, which fall under the AUB-O category in the PALM-COEIN classification system.
How do doctors treat heavy AUB without surgery?
Non-surgical treatments for AUB include hormonal medications (such as the levonorgestrel-releasing IUD, oral contraceptive pills, or oral progestins) and non-hormonal medications (such as tranexamic acid or NSAIDs). These therapies work by stabilizing the uterine lining, reducing vascular breakdown, or managing systemic clotting mechanisms.
Practical Next Steps for Patients
If you are experiencing symptoms of abnormal uterine bleeding, taking proactive, organized steps can help streamline your medical evaluation:
- Maintain a Detailed Menstrual Log: Track your bleeding daily using a specialized smartphone app or a paper journal. Record cycle start and end dates, the estimated number of pads or tampons used each day, whether you passed blood clots, and any associated symptoms like cramping or pelvic pain.
- Gather Medication and Medical Records: Prepare a complete list of all current prescription medications, over-the-counter drugs, and herbal supplements you take. Note any family history of bleeding disorders, early-onset uterine fibroids, or gynecologic cancers.
- Schedule an Initial Consultation: Make an appointment with a primary care provider or an obstetrician-gynecologist. Inform the office staff if you are experiencing unusually heavy bleeding or systemic signs of anemia like severe fatigue or lightheadedness.
- Prepare Specific Questions for Your Care Team: Ask your provider which PALM-COEIN category your symptoms suggest, what initial imaging or laboratory tests are recommended, and which treatment options align best with your health priorities and reproductive plans.